Zymeworks (ZYME) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Executive summary
The annual meeting is scheduled for December 10, 2024, with voting on director elections, executive compensation, and auditor ratification.
Shareholders can vote online, by phone, or by mail, with detailed instructions provided for each method.
Proxy materials are distributed primarily via the Internet to reduce costs and environmental impact.
The Board recommends voting for all director nominees, for executive compensation, and for auditor ratification.
Voting matters and shareholder proposals
Four Class III directors are nominated for election to serve until the 2027 annual meeting.
Advisory vote on executive compensation (say-on-pay) is included.
Ratification of KPMG LLP as auditors for the year ending December 31, 2024.
Shareholders may submit proposals or director nominations for the 2025 annual meeting, following advance notice and procedural requirements.
Board of directors and corporate governance
The Board consists of a majority of independent directors, with a lead independent director appointed due to the CEO also serving as Chair.
Board committees include audit, compensation, nominating and corporate governance, and research and development, each with independent members.
Board diversity is considered in nominations, with recent appointments reflecting a commitment to diverse backgrounds.
Directors are elected to staggered three-year terms, supporting continuity and stability.
Latest events from Zymeworks
- Key votes include director elections, executive pay, and auditor ratification at the 2024 meeting.ZYME
Proxy filing18 May 2026 - Board recommends approval of all proposals, with strong focus on governance and performance-based pay.ZYME
Proxy filing18 May 2026 - Q3 revenue up 73% on milestone and royalty gains, with narrowed net loss and strong cash runway.ZYME
Q3 202518 May 2026 - Virtual annual meeting on Dec 30, 2025, covers director elections, pay, and auditor ratification.ZYME
Proxy filing18 May 2026 - FDA Priority Review, $250M royalty loan, and robust pipeline drive long-term value.ZYME
Q1 202618 May 2026 - Robust pipeline advances and strong cash position drive a royalty-focused growth strategy.ZYME
The Citizens Life Sciences Conference 202615 May 2026 - Hybrid biotech-royalty model, strong pipeline, and $250M financing drive growth and flexibility.ZYME
TD Cowen 46th Annual Health Care Conference28 Apr 2026 - Strong financials and innovation drive growth, with key catalysts and pipeline advances ahead.ZYME
2026 Bloom Burton & Co. Healthcare Investor Conference21 Apr 2026 - Transitioning to a hybrid R&D and asset aggregation model, with strong cash and pipeline momentum.ZYME
25th Annual Needham Virtual Healthcare Conference15 Apr 2026